Kurt A. Gustafson
2012 - Halozyme Therapeutics
Compensation breakdown
Non-Equity Incentive Plan | $47,454 |
---|---|
Option Awards | $318,540 |
Salary | $372,186 |
Stock Awards | $1,120,770 |
Other | $7,888 |
Total | $1,866,838 |
Gustafson received $1.1M in stock awards, accounting for 60% of the total pay in 2012.
Gustafson also received $47.5K in non-equity incentive plan, $318.5K in option awards, $372.2K in salary and $7.9K in other compensation.
Rankings
In 2012, Kurt A. Gustafson's compensation ranked 3,813th out of 11,487 executives tracked by ExecPay. In other words, Gustafson earned more than 66.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,813 out of 11,487 | 67th |
Division Manufacturing | 1,326 out of 4,253 | 69th |
Major group Chemicals And Allied Products | 296 out of 1,198 | 75th |
Industry group Drugs | 175 out of 920 | 81st |
Industry Biological Products, Except Diagnostic Substances | 33 out of 160 | 79th |
Gustafson's colleagues
We found five more compensation records of executives who worked with Kurt A. Gustafson at Halozyme Therapeutics in 2012.
2012
Gregory Frost
Halozyme Therapeutics
Chief Executive Officer
2012
H Shepard
Halozyme Therapeutics
Chief Scientific Officer
2012
James Shaffer
Halozyme Therapeutics
Former Vice President and Chief Commercial Officer
2012
Jean Liu
Halozyme Therapeutics
General Counsel
2012
David Ramsay
Halozyme Therapeutics
Chief Financial Officer
News
April 26, 2024
May 1, 2023
April 27, 2022
April 22, 2020
April 23, 2019